Organic compounds -- part of the class 532-570 series inventions

20090275746 - Solid faropenem free acid: The present invention provides solid form of faropenem free acid, its hydrates and processes for their preparation thereof. Thus, for example, dissolving an alkali metal salt of faropenem in water, adjusting the pH of the solution formed with an acid to below about 2.5 and collecting the precipitated solid to... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090275747 - Methods for the preparation of salts of 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxyl]ethanol (quetiapine) and for the purification thereof: A method for the preparation of salts of 2-[2-(4-dibenzo[b,fj[1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol (quetiapine) from the quetiapine base and the respective acid, wherein the salt is precipitated from a mixture of solvents, the mixture being either a mixture of an aromatic hydrocarbon and a ketone or ester, or that of an aromatic hydrocarbon, water... Agent: Pearl Cohen Zedek Latzer, LLP

20090275748 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090275749 - Production method of optically active piperazine compound: n

20090275750 - Dipeptidyl peptidase inhibitors: Methods of making compounds of the formula (I) wherein the variables are as defined herein. Also, methods of making compounds that may be used to inhibit dipeptidyl peptidase.... Agent: Takeda San Diego, Inc.

20090270610 - Naphthalocyanine compound and method for producing the same: wherein R111, R121, R131 and R141 represent a group of formula (II); R112, R122, R132 and R142 represent a substituent; M1 represents two hydrogen atoms, two monovalent metal atoms, etc.; n112, n122, n132 and n142 are 0 to 4; R211-R218 represent H or a substituent; X211 and X212 represent —O—,... Agent: Sughrue Mion, PLLC

20090270611 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090270612 - Therapeutic agent for osteoporosis using a retinoid x receptor-related compound: n

20090270613 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090270614 - Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same: n

20090264642 - Anhydrous crystal of bata-lactam compound and method for preparation thereof: P

20090264643 - Process for the preparation of beta-lactam antibiotic: The present invention relates to a process for the preparation of Meropenem of formula (I) in sterile form and also provides an improved process for the preparation of compound of formula (V), which is an important intermediate in the synthesis of Meropenem.... Agent: Oliff & Berridge, PLC

20090264644 - Novel macrolide compounds with antibiotic and antineoplastic properties: The invention is drawn to novel macrolide compounds of formula I having antibiotic and antineoplastic activities, useful as medicaments and/or agrochemicals for microorganism infections, in particularly for infectious diseases involving drug-resistant Staphylococcus, and for treatment of human and animal cancers.... Agent: Weihe Wang

20090264645 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090264646 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090264647 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090264648 - Synthesis of pyrazoles: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.... Agent: Choate, Hall & Stewart LLP

20090264649 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Genomics Institute Of The Novartis Research Foundation